HRCT biomarkers
Diagnostic TestHRCT imaging biomarkers of airways, vessels, and overall extent of fibrosis
NCT Number: NCT06472362
The goal of this retrospective observational study is to investigate whether novel imaging biomarkers of airways, vessels, and overall extent of fibrosis at baseline predict ILD progression, vasculopathy development, and survival in SSc-ILD.
Interested in participating?
Request Info18 year–99 year
All sexes
Observational
Bichat-Claude Bernard hospital, Paris, France
Interstitial lung disease (ILD or lung fibrosis=stiffening of the lungs by scar tissue) develops in over half of patients with systemic sclerosis (SSc). Whilst ILD remains stable in some patients, at least a third have progressively increasing fibrosis. There is a pressing need for accurate indicators that identify a) patients at higher risk of progression, needing immediate treatment to prevent further irreversible ILD; and b) patients at lower risk, not needing treatment.
In this study the prognostic potential and accuracy of machine-learning derived biomarkers to evaluate abnormalities that are difficult to quantify visually will be investigated. Whether novel high resolution computed tomography (HRCT) imaging biomarkers of airways, vessels, and overall extent of fibrosis at baseline can predict ILD progression, vasculopathy development, and survival will be investigated in a cohort of approximately 1,000 SSc-ILD patients.
The algorithm scores will be evaluated against survival using Cox proportional hazards modelling, while mixed effects model analysis will be used to assess links with change in lung function: forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLco), and carbon monoxide transfer coefficient (Kco). The airway algorithm measuring traction bronchiectasis (dilatation of the airways due to surrounding fibrosis) may predict worsening of FVC, reflective of ILD progression. The vessel algorithm may predict decline in KCO, a marker of pulmonary vascular involvement. Exploratory analyses evaluating change in HRCT fibrosis extent over time for patients with repeat HRCTs will also be performed, and whether composite outcomes of change in HRCT and lung function variables improve long term outcome prediction and pave the way to their use in clinical trials and routine clinical use. Patients with trivial changes on CT will also be included to assess for very early changes that could be predictive of future decline. These algorithms will be combined with the findings of our previous study, which suggest that a certain type of pattern on CT called UIP predicts shorter survival.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
HRCT imaging biomarkers of airways, vessels, and overall extent of fibrosis
Time frame: 15 years
Transplant-free survival
Time frame: 15 years
Development of pulmonary hypertension
Time frame: 15 years
Change in lung function measure FVC
Time frame: 15 years
Change in lung function measure DLCO
Time frame: 15 years
Change in lung function measure KCO
Royal Brompton & Harefield NHS Foundation Trust
Other
Deep-learning Derived Chest Computed Tomography (CT) Biomarkers as Prognostic Predictors in Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07038447
Autoimmune Diseases, Connective Tissue Diseases
Duarte, California, United States
View Trial DetailsNCT06888973
Ankylosing Spondylitis (AS), Ankylosis
Rawalpindi, Pakistan
View Trial DetailsNCT05108857
Connective Tissue Diseases, Scleroderma, Systemic
Turku, Finland
View Trial DetailsNCT05859997
ANCA Associated Systemic Vasculitis, Antiphospholipid Syndrome
Shanghai, Shanghai Municipality, China
View Trial Details